{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:21:25Z","timestamp":1768321285361,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40265-015-0519-2","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T02:28:27Z","timestamp":1452479307000},"page":"315-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion"],"prefix":"10.1007","volume":"76","author":[{"name":"Working Group Nientemale DEI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-7920","authenticated-orcid":false,"given":"R.","family":"Vellucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pannuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Peruselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Consoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lo Presti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Marinangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Miotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Moruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Romualdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"519_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","volume":"41","author":"RK Portenoy","year":"1990","unstructured":"Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273\u201381.","journal-title":"Pain."},{"key":"519_CR2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.10249","volume":"94","author":"S Mercadante","year":"2002","unstructured":"Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832\u20139.","journal-title":"Cancer."},{"key":"519_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejpain.2008.06.014","volume":"13","author":"AN Davies","year":"2009","unstructured":"Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331\u20138.","journal-title":"Eur J Pain."},{"key":"519_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0885-3924(00)00161-5","volume":"20","author":"G Zeppetella","year":"2000","unstructured":"Zeppetella G, O\u2019Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87\u201392.","journal-title":"J Pain Symptom Manage."},{"key":"519_CR5","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58\u201368.","journal-title":"Lancet Oncol."},{"key":"519_CR6","doi-asserted-by":"crossref","unstructured":"Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014;47(4):772\u2013785.e5.","DOI":"10.1016\/j.jpainsymman.2013.05.020"},{"key":"519_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/JPR.S40745","volume":"6","author":"HS Smith","year":"2013","unstructured":"Smith HS. Considerations in selecting rapid-onset opioids for the management of breakthrough pain. J Pain Res. 2013;6:189\u2013200.","journal-title":"J Pain Res."},{"key":"519_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1191\/0269216304pm890oa","volume":"18","author":"A Caraceni","year":"2004","unstructured":"Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177\u201383.","journal-title":"Palliat Med."},{"key":"519_CR9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpainsymman.2013.02.015","volume":"47","author":"S Deandrea","year":"2014","unstructured":"Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47:57\u201376.","journal-title":"J Pain Symptom Manage."},{"key":"519_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/AJP.0b013e3181edc250","volume":"27","author":"MT Greco","year":"2011","unstructured":"Greco MT, Corli O, Montanari M, et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011;27:9\u201318.","journal-title":"Clin J Pain."},{"key":"519_CR11","first-page":"17","volume":"10","author":"S Mercadante","year":"2010","unstructured":"Mercadante S, Amadori D, Apolone G, et al. Raccomandazioni per la gestione del Breakthrough cancer Pain (BTcP). Riv Ital Cure Palliat. 2010;10:17\u201323.","journal-title":"Riv Ital Cure Palliat."},{"key":"519_CR12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12325-012-0022-z","volume":"29","author":"A Gatti","year":"2012","unstructured":"Gatti A, Mediati RD, Reale C, et al. Breakthrough pain in patients referred to pain clinics: the Italian pain network retrospective study. Adv Ther. 2012;29:464\u201372.","journal-title":"Adv Ther."},{"key":"519_CR13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/JPR.S36428","volume":"5","author":"C Margarit","year":"2012","unstructured":"Margarit C, Julia J, Lopez R, et al. Breakthrough cancer pain\u2014still a challenge. J Pain Res. 2012;5:559\u201366.","journal-title":"J Pain Res."},{"key":"519_CR14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejpain.2010.08.001","volume":"15","author":"AK Knudsen","year":"2011","unstructured":"Knudsen AK, Brunelli C, Kaasa S, et al. Which variables are associated with pain intensity and treatment response in advanced cancer patients? Implications for a future classification system for cancer pain. Eur J Pain. 2011;15:320\u20137.","journal-title":"Eur J Pain."},{"key":"519_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/104990919801500105","volume":"15","author":"PH Coluzzi","year":"1998","unstructured":"Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care. 1998;15:13\u201322.","journal-title":"Am J Hosp Palliat Care."},{"issue":"Suppl 1","key":"519_CR16","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1526-4637.2006.00269.x","volume":"8","author":"R Payne","year":"2007","unstructured":"Payne R. Recognition and diagnosis of breakthrough pain. Pain Med. 2007;8(Suppl 1):S3\u20137.","journal-title":"Pain Med."},{"key":"519_CR17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0304-3959(02)00293-2","volume":"101","author":"SS Hwang","year":"2003","unstructured":"Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55\u201364.","journal-title":"Pain."},{"key":"519_CR18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.pain.2010.02.035","volume":"149","author":"DF Haugen","year":"2010","unstructured":"Haugen DF, Hjermstad MJ, Hagen N, et al. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476\u201382.","journal-title":"Pain."},{"key":"519_CR19","unstructured":"Simmonds MA. Management of breakthrough pain due to cancer. Oncology (Williston Park). 1999;13:1103\u20138 (discussion 1110, 1113\u20131114)."},{"key":"519_CR20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpainsymman.2007.03.016","volume":"35","author":"NA Hagen","year":"2008","unstructured":"Hagen NA, Stiles C, Nekolaichuk C, et al. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manage. 2008;35:136\u201352.","journal-title":"J Pain Symptom Manage."},{"issue":"4","key":"519_CR21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpainsymman.2013.10.026","volume":"48","author":"K Webber","year":"2014","unstructured":"Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage. 2014;48(4):619\u201331.","journal-title":"J Pain Symptom Manage."},{"key":"519_CR22","first-page":"296","volume":"30","author":"D Bennett","year":"2005","unstructured":"Bennett D, Burton AW, Fishman S, et al. Consensus Panel recommendations for the assessment and management of breakthrough pain. Part I assessment. Pharm Ther. 2005;30:296\u2013301.","journal-title":"Pharm Ther."},{"key":"519_CR23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1471-6712.2008.00601.x","volume":"23","author":"R Jacobsen","year":"2009","unstructured":"Jacobsen R, Moldrup C, Christrup L, Sjogren P. Patient-related barriers to cancer pain management: a systematic exploratory review. Scand J Caring Sci. 2009;23:190\u2013208.","journal-title":"Scand J Caring Sci."},{"key":"519_CR24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00002820-200204000-00009","volume":"25","author":"KL Schumacher","year":"2002","unstructured":"Schumacher KL, West C, Dodd M, et al. Pain management autobiographies and reluctance to use opioids for cancer pain management. Cancer Nurs. 2002;25:125\u201333.","journal-title":"Cancer Nurs."},{"key":"519_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0885-3924(02)00385-8","volume":"23","author":"KL Schumacher","year":"2002","unstructured":"Schumacher KL, Koresawa S, West C, et al. Putting cancer pain management regimens into practice at home. J Pain Symptom Manage. 2002;23:369\u201382.","journal-title":"J Pain Symptom Manage."},{"key":"519_CR26","doi-asserted-by":"crossref","unstructured":"American Pain F. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25:252\u201364.","DOI":"10.3109\/15360288.2011.599920"},{"key":"519_CR27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1054\/jpai.2002.27136","volume":"3","author":"BV Fortner","year":"2002","unstructured":"Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38\u201344.","journal-title":"J Pain."},{"key":"519_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0885-3924(02)00597-3","volume":"25","author":"BV Fortner","year":"2003","unstructured":"Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25:9\u201318.","journal-title":"J Pain Symptom Manage."},{"key":"519_CR29","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1001\/jama.279.23.1877","volume":"279","author":"R Bernabei","year":"1998","unstructured":"Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic assessment of geriatric drug use via epidemiology. JAMA. 1998;279:1877\u201382.","journal-title":"JAMA."},{"key":"519_CR30","first-page":"23","volume-title":"Cancer-related breakthrough pain","author":"D Laverty","year":"2006","unstructured":"Laverty D, Davies A. Assessment. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 23\u201330."},{"key":"519_CR31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00520-013-1747-1","volume":"21","author":"K Oechsle","year":"2013","unstructured":"Oechsle K, Goerth K, Bokemeyer C, Mehnert A. Symptom burden in palliative care patients: perspectives of patients, their family caregivers, and their attending physicians. Support Care Cancer. 2013;21:1955\u201362.","journal-title":"Support Care Cancer."},{"key":"519_CR32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1477-7525-8-104","volume":"8","author":"EA Laugsand","year":"2010","unstructured":"Laugsand EA, Sprangers MA, Bjordal K, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes. 2010;8:104.","journal-title":"Health Qual Life Outcomes."},{"key":"519_CR33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/0269216305pm958oa","volume":"19","author":"JL Parlow","year":"2005","unstructured":"Parlow JL, Milne B, Tod DA, et al. Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series. Palliat Med. 2005;19:3\u20138.","journal-title":"Palliat Med."},{"key":"519_CR34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/JPR.S54788","volume":"6","author":"BC Bell","year":"2013","unstructured":"Bell BC, Butler EB. Management of predictable pain using fentanyl pectin nasal spray in patients undergoing radiotherapy. J Pain Res. 2013;6:843\u20138.","journal-title":"J Pain Res."},{"key":"519_CR35","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00520-010-1062-z","volume":"19","author":"K Webber","year":"2011","unstructured":"Webber K, Davies AN, Cowie MR. Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer. 2011;19:2041\u20136.","journal-title":"Support Care Cancer."},{"key":"519_CR36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.suponc.2010.10.006","volume":"8","author":"MI Rhiner","year":"2010","unstructured":"Rhiner MI, von Gunten CF. Cancer breakthrough pain in the presence of cancer-related chronic pain: fact versus perceptions of health-care providers and patients. J Support Oncol. 2010;8:232\u20138.","journal-title":"J Support Oncol."},{"issue":"Suppl 1","key":"519_CR37","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.6004\/jnccn.2013.0213","volume":"11","author":"G Zeppetella","year":"2013","unstructured":"Zeppetella G. Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw. 2013;11(Suppl 1):S37\u201343.","journal-title":"J Natl Compr Canc Netw."},{"key":"519_CR38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1185\/03007991003694340","volume":"26","author":"D Vissers","year":"2010","unstructured":"Vissers D, Stam W, Nolte T, et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037\u201345.","journal-title":"Curr Med Res Opin."},{"key":"519_CR39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/15748871112079990039","volume":"8","author":"F Meriggi","year":"2013","unstructured":"Meriggi F, Zaniboni A. Fentanyl for breakthrough cancer pain: where are we? Rev Recent Clin Trials. 2013;8:42\u20137.","journal-title":"Rev Recent Clin Trials."},{"key":"519_CR40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.clinthera.2014.01.006","volume":"36","author":"S Novotna","year":"2014","unstructured":"Novotna S, Valentova K, Fricova J, Richterova E, Harabisova S, Bullier F. Trinquet F; ETHYFYL Study Group. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther. 2014;36:357\u201367.","journal-title":"Clin Ther."},{"key":"519_CR41","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.clinthera.2009.05.022","volume":"31","author":"HG Kress","year":"2009","unstructured":"Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177\u201391.","journal-title":"Clin Ther."},{"key":"519_CR42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.ajp.0000210932.27945.4a","volume":"22","author":"RK Portenoy","year":"2006","unstructured":"Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805\u201311.","journal-title":"Clin J Pain."},{"key":"519_CR43","first-page":"327","volume":"5","author":"NE Slatkin","year":"2007","unstructured":"Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327\u201334.","journal-title":"J Support Oncol."},{"key":"519_CR44","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1185\/03007990903336135","volume":"25","author":"S Mercadante","year":"2009","unstructured":"Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805\u201315.","journal-title":"Curr Med Res Opin."},{"key":"519_CR45","doi-asserted-by":"crossref","unstructured":"Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013;10:CD004311.","DOI":"10.1002\/14651858.CD004311.pub3"},{"key":"519_CR46","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/0269216310385601","volume":"25","author":"G Zeppetella","year":"2011","unstructured":"Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med. 2011;25:516\u201324.","journal-title":"Palliat Med."},{"key":"519_CR47","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.bjc.6603811","volume":"96","author":"S Mercadante","year":"2007","unstructured":"Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007;96:1828\u201333.","journal-title":"Br J Cancer."},{"key":"519_CR48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/jpm.2006.0151","volume":"10","author":"NA Hagen","year":"2007","unstructured":"Hagen NA, Fisher K, Victorino C, Farrar JT. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med. 2007;10:47\u201355.","journal-title":"J Palliat Med."},{"key":"519_CR49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3959(00)00427-9","volume":"91","author":"PH Coluzzi","year":"2001","unstructured":"Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123\u201330.","journal-title":"Pain."},{"key":"519_CR50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","volume":"81","author":"RK Portenoy","year":"1999","unstructured":"Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129\u201334.","journal-title":"Pain."},{"key":"519_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SPC.0b013e3283260658","volume":"3","author":"G Zeppetella","year":"2009","unstructured":"Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3:1\u20136.","journal-title":"Curr Opin Support Palliat Care."},{"key":"519_CR52","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1185\/03007995.2013.837816","volume":"29","author":"GH Hans","year":"2013","unstructured":"Hans GH. Treatment of breakthrough cancer pain: to titrate or to proportionate? Curr Med Res Opin. 2013;29:1523\u20136.","journal-title":"Curr Med Res Opin."},{"key":"519_CR53","doi-asserted-by":"crossref","first-page":"09","DOI":"10.2165\/11630580-000000000-00000","volume":"26","author":"H Smith","year":"2012","unstructured":"Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs. 2012;26:09\u2013535.","journal-title":"CNS Drugs."},{"key":"519_CR54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2710.2010.01239.x","volume":"37","author":"L Sima","year":"2012","unstructured":"Sima L, Fang WX, Wu XM, Li F. Efficacy of oxycodone\/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther. 2012;37:27\u201331.","journal-title":"J Clin Pharm Ther."},{"key":"519_CR55","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1200\/JCO.2011.35.0561","volume":"29","author":"B Breuer","year":"2011","unstructured":"Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists\u2019 attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29:4769\u201375.","journal-title":"J Clin Oncol."},{"key":"519_CR56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SPC.0b013e3283434515","volume":"5","author":"A Dickman","year":"2011","unstructured":"Dickman A. Integrated strategies for the successful management of breakthrough cancer pain. Curr Opin Support Palliat Care. 2011;5:8\u201314.","journal-title":"Curr Opin Support Palliat Care."},{"key":"519_CR57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5055\/jom.2010.0029","volume":"6","author":"RK Portenoy","year":"2010","unstructured":"Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manage. 2010;6:319\u201328.","journal-title":"J Opioid Manage."},{"key":"519_CR58","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdp541","volume":"21","author":"R Rauck","year":"2010","unstructured":"Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308\u201314.","journal-title":"Ann Oncol."}],"updated-by":[{"DOI":"10.1007\/s40265-016-0563-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:00:00Z","timestamp":1459987200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0519-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0519-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0519-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:07:39Z","timestamp":1553612859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0519-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0519-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-016-0563-6","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}